August 1, 2012 (Pulmonary & Critical Care)
"A New Frontier in Critical Care: Saving the Injured Brain"
Wesley Ely, M.D.
Professor of Medicine with Tenure, Department of Medicine – Vanderbilt University School of Medicine
Intensivist and Pulmonary/Critical Care Consultant; Attending Physician – Vanderbilt University Medical Center
Associate Director; Research - VA TN Valley Health Care System; Geriatric Research Education Clinical Center; Department of Veterans Affairs Medical Center
Attending Physician, Department of Veterans Affairs Medical Center
Nashville, TN

Objectives:
- Discuss the prevalence of and risk factors for delirium in the ICU.
- Discuss varying clinical presentations of delirium and the therapeutic approaches currently used.
- Review recent advances in delirium monitoring for critically ill patients.
- Review data regarding delirium and its association with outcomes including length of stay, cost, and mortality.
- Introduce the concept of long-term cognitive impairment as an unrecognized complication of critical illness.

August 8, 2012
"Biologic Therapy in Rheumatoid Arthritis, What Primary Care Doctors Need to Know"
Catalina Orozco, M.D.
Rheumatology, Texas Health Presbyterian Hospital Dallas; Rheumatology Associates – Dallas, Texas

Objectives:
- Identify some common side effects from biologic therapy in rheumatoid arthritis.
- Discuss the risks and benefits of biologic therapy in rheumatoid arthritis.

August 15, 2012
"Scleroderma Management in 2012: Are we Doing Better"
Maureen D. Mayes, M.D., M.P.H.
Professor of Internal Medicine; Elizabeth Bidgood Chair in Rheumatology; Division of Rheumatology and Clinical Immunogenetics
University of Texas – Houston Medical School – Houston, Texas

Objectives:
- Develop a plan to identify internal organ involvement, particularly pulmonary and pulmonary vascular disease for the evaluation of a newly diagnosed SSc patient.
- Develop a plan for monitoring for disease progression for an established scleroderma patient.

August 22, 2012
"Mechanism-Based Treatment of Systemic Lupus Erythematosus- Are We There Yet?"
David Karp, M.D.
Professor and Chief, Rheumatic Disease Division – U.T. Southwestern Medical Center – Dallas, Texas

Objectives:
- Discuss the current concepts underlying the etiopathogenesis of SLE.
- Review the strengths and limitations of current and proposed therapies for SLE.

Teaching Method: Didactic Lecture with Question and Answer Session
Target Audience: Internal Medicine Physicians; Residents; Physician Assistants; Nurse Practitioners; Nurses; Allied Health

Texas Health Research & Education Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Texas Health Research & Education Institute designates this live activity for a maximum of 1 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in this activity.

*Doctors on the medical staff practice independently and are not employees or agents of the hospital.

For more information, please contact the CME department at 214-345-2323 option 1, email cme@texashealth.org, or visit our website www.texashealth.org/CME.